{"id":11301,"date":"2020-05-05T15:13:33","date_gmt":"2020-05-05T14:13:33","guid":{"rendered":"https:\/\/montpellier-cancer.com\/?page_id=11301"},"modified":"2023-11-23T17:54:05","modified_gmt":"2023-11-23T16:54:05","slug":"antibody-engineering-genac-platform","status":"publish","type":"page","link":"https:\/\/montpellier-cancer.com\/en\/recherche\/plateformes-en-cancerologie\/antibody-engineering-genac-platform\/","title":{"rendered":"Antibody engineering \u2013 GenAc Platform"},"content":{"rendered":"
\n
\n
\n

The GenAc platform is dedicated to the development of original antibodies for therapeutic and diagnostic applications using phage display. Antibodies are selected and produced fully in vitro without preclinical model immunization. The recombinant monoclonal antibodies thus produced can be freely reformatted according to the planed applications. Currently, the platform can produce antibodies in human (IgG1 kappa or lambda), preclinical model (IgG2a) or rabbit (IgG) format with a wild type, an inactive or an improved Fc fragment.<\/p>\n<\/div>\n <\/div>\n <\/div>\n <\/div>\n\n\n

\n
\n
\n
\n

Conditions of access<\/h2>\n <\/div>\n
\n
\n
\n

You can apply to work with the platform by filling in the Project Form and sending it to the following: GenAc@icm.unicancer.fr<\/a><\/p>\n

Applications are submitted to a Selection Committee, which will establish an order of priority. Any project submitted by a French or foreign team will be processed by the platform on a collaborative basis. This committee meets regularly 2 or 3 times a year.<\/p>\n

Once your application has been submitted, you will receive an e-mail indicating the date of the next committee meeting and putting you in touch with the platform managers.<\/p>\n\n <\/div>\n\n